Patrik Renblad
Vermogen: 26 957 $ op 31-08-2026
Vermogen: 26 957 $ op 31-08-2026
Patrik Renblad is currently the Chief Financial Officer at Cantargia AB since 2023.
Prior to this, he was the Chief Financial Officer at SynAct Pharma AB from 2022 to 2023.
He also worked as a Finance Director-R&D at LEO Pharma A. Mr. Renblad is a graduate of the University of Lund.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CANTARGIA AB 0,05% | 31-12-2024 | 141.405 ( 0,05% ) | 26 957 $ | 31-08-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CANTARGIA AB | Financieel Directeur/CFO | 15-06-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
| SYNACT PHARMA AB | Financieel Directeur/CFO | 15-05-2023 |
LEO Pharma A/S
LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Health Services |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
SynAct Pharma AB
SynAct Pharma AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs for treatment inflammatory diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau